Selective effects of thiazide therapy on serum 1 alpha,25-dihydroxyvitamin D and intestinal calcium absorption in renal and absorptive hypercalciurias.
The effect of long-term thiazide therapy (hydrochlorothiazide, 50 mg twice/day) on intestinal calcium (Ca) absorption and serum 1 alpha,25-dihydroxyvitamin D [1 alpha,25-(OH)2D] concentration was examined in 10 patients with renal hypercalciuria (RH), many of whom had hyperabsorption of Ca, and in 11 cases of absorptive hypercalciuria (AH), all of whom had intestinal hyperabsorption of Ca. In patients with RH, the intestinal Ca absorption decreased significantly during thiazide therapy (mean treatment period of 15 mo) from 0.68 +/- 0.09 SD to 0.56 +/- 0.10 (p less than 0.01), commensurate with the "correction" of the renal leak of Ca and secondary hyperparathyroidism. Furthermore, serum 1 alpha,25-(OH)2D decreased significantly from 5.2 +/- 2.2 SD ng/dl to 3.7 +/- 0.8 ng/dl (p less than 0.025) during thiazide therapy. In patients with AH, the intestinal hyperabsorption of calcium persisted during thiazide treatment (0.69 +/- 0.07 versus 0.69 +/- 0.06), despite restoration of normal urinary Ca. Serum 1 alpha,25-(OH)2D was virtually unchanged during treatment (4.5 +/- 1.4 ng/dl versus 4.7 +/- 0.9 ng/dl). The results support the hypothesis that the intestinal hyperabsorption of Ca in RH is a result of increased serum concentration of 1 alpha,25-(OH)2D secondary to the hyperparathyroid state, while that in AH may not be totally dependent on increased concentrations of 1 alpha,25-(OH)2D.
D000328:Adult; D001581:Benzothiadiazines; D002118:Calcium / Q000378:metabolism* / Q000652:urine; D004100:Dihydroxycholecalciferols / Q000009:adverse effects / Q000378:metabolism*; D004232:Diuretics; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000378:metabolism*; D007408:Intestinal Absorption; D007410:Intestinal Diseases / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D007674:Kidney Diseases / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D049993:Sodium Chloride Symporter Inhibitors / Q000378:metabolism* / Q000627:therapeutic use
D001581:Benzothiadiazines; D004100:Dihydroxycholecalciferols; D004232:Diuretics; D006887:Hydroxycholecalciferols; D049993:Sodium Chloride Symporter Inhibitors; D002118:Calcium